Repros Therapeutics

CompanyUnited StatesFounded 1987

Repros Therapeutics develops one asset, in phase 2 (enclomiphene citrate in secondary hypogonadism). Mostly small molecule acting on ESR2 and ESR1; based in the United States, founded in 1987.

1
Asset
Furthest: Phase 2; 6
Trials: 0
Signals

Pipeline

1

enclomiphene citrate
Selective estrogen receptor modulator stimulating endogenous testosterone production
Phase 2, Small molecule, ESR2, ESR1, secondary hypogonadism

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials6
Similar companies6

Updated 11 Oct 2026 · 10 sources